4//SEC Filing
Manning Donald C. 4
Accession 0001209191-19-028146
CIK 0001054274other
Filed
May 6, 8:00 PM ET
Accepted
May 7, 8:55 PM ET
Size
14.9 KB
Accession
0001209191-19-028146
Insider Transaction Report
Form 4
Manning Donald C.
CHIEF MEDICAL OFFICER
Transactions
- Award
Stock Option (Right to Buy)
2019-05-03+23,858→ 23,858 totalExercise: $1.11Exp: 2022-03-07→ Common Stock (23,858 underlying) - Award
Stock Option (Right to Buy)
2019-05-03+7,887→ 7,887 totalExercise: $1.39Exp: 2022-07-16→ Common Stock (7,887 underlying) - Award
Stock Option (Right to Buy)
2019-05-03+3,943→ 3,943 totalExercise: $1.39Exp: 2022-12-17→ Common Stock (3,943 underlying) - Award
Stock Option (Right to Buy)
2019-05-03+56,407→ 56,407 totalExercise: $3.06Exp: 2026-12-15→ Common Stock (56,407 underlying)
Footnotes (5)
- [F1](1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding.
- [F2](2) On March 8, 2012, Reporting Person was granted an option to purchase 664,560 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,858 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested.
- [F3](3) On July 17, 2012, Reporting Person was granted an option to purchase 219,684 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,887 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
- [F4](4) On December 18, 2012, Reporting Person was granted an option to purchase 109,842 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,943 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
- [F5](5) On December 16, 2016, Reporting Person was granted an option to purchase 1,571,214 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 56,407 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable.
Documents
Issuer
Alliqua BioMedical, Inc.
CIK 0001054274
Entity typeother
Related Parties
1- filerCIK 0001775268
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 8:55 PM ET
- Size
- 14.9 KB